Breakthrough trial offers hope for Tough-to-Treat stomach cancers
NCT ID NCT07103668
Summary
This study is testing whether a new targeted treatment called IMC002 works better than standard options for people with advanced stomach cancer that has a specific marker called CLDN18.2. It's for patients whose cancer has continued to grow despite trying at least two other treatments. The main goals are to see if IMC002 can slow cancer progression and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.